318
Participants
Start Date
June 1, 2023
Primary Completion Date
September 1, 2025
Study Completion Date
September 30, 2025
Epclusa (nucleotide HCV NS5B polymerase inhibitors).
Sofosbuvir (400mg/day) and Velpatasvir(100mg/day) for 12 weeks or 24 weeks
Clinical trials unit, Karachi
Aga Khan University
OTHER
Dow University of Health Sciences
OTHER
University of Oxford
OTHER
University of Bristol
OTHER
Queen Mary University of London
OTHER